990-分子胶抑制剂KRAS耐药机制研究 episode artwork

EPISODE · May 17, 2026 · 19 MIN

990-分子胶抑制剂KRAS耐药机制研究

from 聊聊Sci

这份研究探讨了癌细胞如何对新型 RAS 抑制剂 daraxonrasib 产生耐药性。通过对临床患者样本和临床前模型的分析,研究人员发现特定基因突变会破坏“分子胶”复合体的形成,从而使药物失效。其中,KRAS Y64 突变通过减弱药物与蛋白的结合力产生抗性,而 KRAS Y71 和低活性的 BRAF 突变则通过增强 RAS 与下游效应因子 RAF 的结合,使其难以被药物驱离。研究阐明了这些突变如何协同干扰合成复合体的稳定性,并导致致癌信号通路的持续激活。最后,作者针对这些耐药机制,开发并验证了新型抑制剂及联合用药方案,为改善 RAS 驱动型癌症的疗效提供了机械学蓝图。References:Sang B, Ye L, Fu Z ... Disrupted molecular glue complex drives RAS inhibitor resistance. Cell, 2026; 0前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published May 17, 2026

Embed this episode

Ready to play

990-分子胶抑制剂KRAS耐药机制研究

0:00 19:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 19 minutes long.

When was this 聊聊Sci episode published?

This episode was published on May 17, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!